A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies

This study will evaluate mechanisms of resistance to anti-breast cancer therapies in tumor and blood samples from participants with human epidermal growth factor receptor (HER2) positive, hormone receptor (HR) positive or triple negative breast cancer.

Trial Details

NCT ID

NCT06274515

Phase

PHASE4

Sponsor

Hoffmann-La Roche

Status

RECRUITING

Cancer Type

ER/PR Positive (Hormone Receptor Positive) Breast Cancer

Interventions

Tumor Tissue and Blood Draw

Locations (sample)

Anderlecht, Belgium|50.83619,4.31454
Brasschaat, Belgium|51.2912,4.49182
Liège, Belgium|50.63373,5.56749
Roeselare, Belgium|50.94653,3.12269
Aalborg, Denmark|57.048,9.9187

Key Eligibility Criteria

Willingness to undergo a procedure to obtain tumor tissue (e.g. biopsy) and blood draw
Diagnosis of HER2+, HR+ (for cohort R1) or triple negative breast cancer (for cohort T1) as per local assessment
Availability of an archival tumor tissue (most recent pre-treatment tumor tissue is preferred)
Unequivocally growing tumor lesion (progressive lesion) that is accessible for resection, excision or core needle biopsy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find ER/PR Positive (Hormone Receptor Positive) Breast Cancer Trials on Trialify →